|Treatments:||Chemotherapy, Surgery||Hospital:||Institut Paoli-Calmettes|
Patients: This phase II study involved thirty four patients (median age=50 years) with stage IIIc or IV epithelial ovarian cancer.
Treatment: The treatment consisted of post-operative high-dose chemotherapy with haematopoietic stem cell support. Patients received a post-operative sequential combination of high-dose cyclophosphamide/epirubicin with haematopoietic stem cell harvesting, high-dose carboplatin followed by haematopoietic stem cell infusion, and dose-dense paclitaxel. Rh-G-CSF (filgrastim) was administered following all cycles.
Toxicity: Hematological toxicuty was reported as "severe" and febrile neutropenia requiring hospitalization was experienced by about 75% of patients. In addition, three patients withdrew from the study due to the toxicities they experienced, which included sepsis, inadequate platelet count, pneumonia and reversible grade 3 central neurological alterations that included confusion.
Results: Median overall survival was not reported, but the estimated 5-year overall survival was reported as 40%. The authors concluded that the observed response rate "does not support a clear advantage (of this protocol) over conventional treatment."
Correspondence: Dr. A. Goncalves